Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial
Survodutide markedly reduced liver fat and weight in people with fatty liver disease, offering a promising new treatment option for this currently drug-limited condition.
The SYNCHRONIZE-MASLD phase 3 RCT demonstrates that survodutide, a novel glucagon/GLP-1 dual agonist, produces dramatic liver fat reduction and significant weight loss in MASLD/MASH patients, markedly outperforming placebo on both co-primary endpoints in a well-controlled 48-week trial. Published in Nature Medicine, this represents a potentially practice-changing therapeutic option for a condition currently lacking approved pharmacotherapy with proven histological benefit at this magnitude.
What the study was
- Study design
- Phase 3 randomized, double-blind, placebo-controlled trial (2:1 allocation)
- Population
- Adults with obesity (BMI ≥30 or ≥27 with complication) and at-risk MASLD (confirmed by NITs or biopsy-confirmed MASH). US and Spain.
- Sample size
- 216
- Category
- Treatment Innovation
- Maturity
- Potentially Practice-Changing
- Journal
- Nature Medicine
Why it surfaced
Phase 3 RCT published in Nature Medicine for MASLD — a condition with large unmet need affecting ~25% of global adults. Novel dual agonist mechanism differentiates survodutide from existing GLP-1 monotherapy. 84% liver fat response rate with clinically meaningful weight loss. Trial limitations: short duration (48 weeks), limited geographic reach.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.